title: Biologic Therapy in the Treatment of Chronic Skin Disorders.
abstract: Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis. The therapeutic utility of biologic agents for patients with immune-related dermatologic disorders is likely to expand in the future. This article reviews the data regarding biologic agents and their utility in the management of specific skin-related disorders.
authors.affiliation: Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Fernandez
authors.affiliation: Departments of Dermatology and Pathology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Fernandez
authors.affiliation: Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: langd@ccf.org.
authors.forename: David M
authors.initials: DM
authors.lastname: Lang
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D000069444:Omalizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D001688:Biological Products; D007155:Immunologic Factors; D000069444:Omalizumab
keywords: Angioedema; Atopic dermatitis; Biologic agents; Dupilimab; Omalizumab; Psoriasis; Urticaria